Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines Completed Phase 3 Trials for Bordetella pertussis pertactin antigen (DB10789)

Indication	Status	Phase
DBCOND0121368 (Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines)	Completed	3

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT01353703	Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine	Prevention	Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (DB10788) Bordetella pertussis pertactin antigen (DB10789) Bordetella pertussis toxoid antigen (formaldehyde inactivated) (DB14388) Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583) Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584) Haemophilus influenzae b polysaccharide-tetanus conjugate (DB15876) Hepatitis B Vaccine (Recombinant) (DB11627) Pentetic acid (DB14007) Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795) Poliovirus type 2 antigen (formaldehyde inactivated) (DB10796) Poliovirus type 3 antigen (formaldehyde inactivated) (DB10797)